Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | MMP9 | P14780 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | GGT1 | P19440 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461571 | 1.00 | KMT2A (0.54) | KMT2AMMP2MMP9ALDH1A1RAB9A | |
| SCHEMBL27520105 | 0.89 | TLR2 (0.46) | KMT2AMMP2MMP9ALDH1A1RAB9A | |
| SCHEMBL14394199 | 0.88 | KMT2A (0.45) | KMT2AMMP2MMP9ALDH1A1RAB9A | |
| SCHEMBL2251543 | 0.87 | FFAR1 (0.46) | KMT2AMMP2MMP9 | |
| SCHEMBL1818651 | 0.87 | NAALAD2 (0.60) | MMP9NAALAD2MEP1BFOLH1MMP8 | |
| SCHEMBL3387298 | 0.87 | NAALAD2 (0.60) | MMP9NAALAD2MEP1BFOLH1MMP8 | |
| SCHEMBL869873 | 0.87 | NAALAD2 (0.60) | MMP9NAALAD2MEP1BFOLH1MMP8 | |
| SCHEMBL2250167 | 0.86 | L3MBTL1 (0.51) | KMT2AMMP2MMP9ALDH1A1CA2 | |
| SCHEMBL2252839 | 0.86 | FOLH1 (0.49) | KMT2AMMP2MMP9FOLH1CA2 | |
| SCHEMBL2247510 | 0.86 | FOLH1 (0.49) | KMT2AMMP2MMP9ALDH1A1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089417-A2 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS Health (International) Limited (CH) | 2009-08-19 | — | — | EP | claimed |
| WO-2009019534-A2 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (US) | 2009-02-12 | — | — | WO | claimed |
| EP-0552417-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-07 | — | — | EP | claimed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | claimed |
| JP-59080644-A | — | — | None | — | — | JP | disclosed |
| US-20220089639-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | NOVARTIS AG (CH) | 2022-03-24 | — | — | US | disclosed |
| WO-2018067789-A1 | HYDROGEL DISPLAY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-12 | — | — | WO | disclosed |
| CN-103787927-B | Deliver method, compound, compositionss and the carrier of 3 amino 1 propane sulfonic acid | BHI有限合资公司 | 2017-03-01 | — | — | CN | disclosed |
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2386565-A2 | Compounds and methods to inhibit or augment an inflammatory response | Cambridge Enterprise Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20020058622-A1 | Sustained-release preparation | IGARI YASUTAKA (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6376461-B1 | WATER INSOLUBLE OR SLIGHTLY WATER SOLUBLE POLYVALENT METAL SALT OF A GROWTH HORMONE, AND A BIODEGRADABLE POLYMER; ENDOTHELIN ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6251861-B1 | CYCLO(D-ASP-ASP(R1)-ASP-D-THG(2)-LEU-TRP) DISODIUM SALT, WHERE ASP(R1) IS AN ASPARTIC ACID BETA-4-PHENYLPIPERAZINE AMIDE RESIDUE AND THG(2) IS 2-(2-THIENYL)GLYCINE; ANTI-ENDOTHELIN ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0994144-A2 | Polypeptid-polysiloxane copolymers | Th. Goldschmidt AG (DE) | 2000-04-19 | — | — | EP | disclosed |
| EP-0552417-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0815870-A2 | Composition for prohylaxis or treatment of cerebral infarction | Takeda Chemical Industries, Ltd. (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | disclosed |
| JP-S5980644-A | NOVEL ACYLGLUTAMINE DERIVATIVE | FUJISAWA PHARMACEUT CO LTD | 1984-05-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058622-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | KMT2A 2035/4885MMP2 401/4885MMP9 561/4885 |
| US-20220089639-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | PTMS, TGM3, TGM1 | KMT2A 198/4885MMP2 1517/4885MMP9 3272/4885 |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CCL2, CCL5, CCL11 | KMT2A 4863/4885MMP2 177/4885MMP9 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.